High-Dose Fish Oil Can Thin Your Blood Further. Warfarin Users Need to Know

Fish oil is one of the best-selling supplements globally. It is widely taken for heart health, inflammation, and general cardiovascular support. The same properties that make omega-3 fatty acids cardioprotective also make them pharmacologically active in ways that matter for people on blood-thinning medication.

How omega-3s affect clotting

Omega-3 fatty acids, particularly EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), affect blood clotting through multiple pathways.

At the level of platelets, EPA competes with arachidonic acid in the production of thromboxane, a compound that promotes platelet aggregation and blood vessel constriction. EPA-derived thromboxane variants are less potent aggregators. The net effect is reduced platelet stickiness.

There is also evidence that high-dose omega-3s affect other parts of the coagulation cascade, including factors involved in fibrin clot formation.

At typical dietary or supplemental doses of 1–2g of combined EPA and DHA, these effects are modest and generally considered beneficial rather than risky for healthy people. They reduce the risk of arterial clots and may lower cardiovascular event risk.

Where the problem begins

The concern arises when doses exceed roughly 3g of combined EPA and DHA per day, and particularly when omega-3s are combined with anticoagulant or antiplatelet drugs. Warfarin, aspirin, clopidogrel, and novel anticoagulants like rivaroxaban all affect clotting through their own mechanisms.

When a patient’s warfarin dose is calibrated to maintain INR (a measure of clotting time) within a therapeutic window, adding high-dose fish oil to the regimen can push INR higher. The blood thins further. The bleeding risk increases.

Case reports have documented elevated INR and bleeding events in people on stable warfarin therapy after starting high-dose fish oil. The interaction is not hypothetical.

The dose question

The majority of evidence suggests that fish oil at 1–2g per day does not meaningfully alter INR in people on warfarin. The FDA approved a prescription omega-3 formulation (Vascepa) at 4g/day specifically for triglyceride reduction, and clinical trial data on INR was carefully monitored. At 4g/day in combination with anticoagulants, the interaction is considered clinically significant.

For people on warfarin, the practical implication is to inform their anticoagulation clinic or prescriber before starting fish oil, particularly at doses above 1g. INR monitoring is routine for warfarin users and would catch any emerging shift.

---

Reference

1. Examine.com. "Fish Oil: Blood Thinning Properties." examine.com